Lantheus Holdings, Inc.
LNTH
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $6.6B
$100.97
▼ -0.01%
P/E
23.98
Mkt Cap
$6.6B
52-Wk Range
$49.67–$111.86
52-Week Range
$49.67 - $111.86
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 88.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary radiopharmaceutical manufacturing expertise and FDA-approved product portfolio
- Strategic partnerships with global healthcare leaders (GE Healthcare, Bayer, Regeneron) providing distribution and development advantages
- Specialized focus on high-barrier nuclear medicine and molecular imaging markets with limited competition
- Integrated diagnostic and therapeutic capabilities enabling precision medicine solutions
- Established relationships with radio pharmacies, hospitals, and integrated delivery networks
Bear Case
2 risks
- Low volatility (beta -0.1).
- Premium valuation to Large Cap Pharma peers
Growth
Stable outlook
Rising demand for precision oncology and personalized cancer diagnostics and treatment
Value
Premium valuation to Large Cap Pharma peers
Momentum
Stable
-0.0% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying LNTH right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of $1.55 vs $1.30 consensus (+19.2% surprise). Revenue of $388.2M vs $363.2M expected (+6.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+19.2%
Revenue trend · last 8Q
—
+10%
+1%
-4%
+1%
+4%
+1%
+3%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$378.7M
$391.1M
$372.8M
$378.0M
$384.0M
$406.8M
$377.3M
$388.2M
Margins · last 8Q
Gross
62.3%
Operating
25.8%
Profit
19.3%
Wall Street consensus
6 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
—
Latest: CJS · Aug 4, 2026
vs Industry
How LNTH stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related